213
Participants
Start Date
November 30, 2017
Primary Completion Date
October 7, 2019
Study Completion Date
February 27, 2024
Daratumumab
Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.
Velcade
Velcade will be administered at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
Dexamethasone
Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
National Taiwan University Hospital, Taipei
Tri-Service General Hospital, Taipei
Peking Union Medical College Hospital, Beijing
Peking University First Hospital, Beijing
Peking University People s Hospital, Beijing
Peking University Third Hospital, Beijing
The First Hospital of Jilin University, Changchun
Shanghai Changzheng Hospital, Shanghai
Ruijin Hospital Shanghai Jiao Tong University, Shanghai
Nanjing Drum Tower Hospital, Nanjing
Zhongda Hospital Southeast University, Nanjing
Jiangsu Province Hospital, Nanjing
First Affiliated Hospital SooChow University, Suzhou
Tianjin cancer hospital, Tianjin
Tianjin Medical University General Hospital, Tianjin
Institute of Hematology and Blood Diseases Hospital, Tianjin
First Affiliated Hospital Medical School of Zhejiang University, Hangzhou
First affiliated Hospital of Zhejiang University, Hangzhou
Fujian Meidical University Union Hospital, Fuzhou
Xinqiao Hospital of the Third Military Medical University, Chongqing
Tongji Hospital, Tongji Medical College of HUST, Wuhan
Henan Cancer Hospital, Zhengzhou
Guangdong Provincial People's Hospital, Guangzhou
The First Affiliated Hospital Sun Yat sen University, Guangzhou
Nanfang Hospital, Guangzhou
West China Hospital Si Chuan University, Chengdu
Tangdu Hospital, Xi'an
Janssen Research & Development, LLC
INDUSTRY